Identification of CHEK2 germline mutations in BRCA1/2 and PALB2 negative breast and ovarian cancer patients.

Creative Commons License

Aksoy F., Tezcan Unlu H., Cecener G., Guney Eskiler G., Egeli Ü., Tunca B., ...Daha Fazla

Human heredity, cilt.87, ss.21-33, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 87
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1159/000521369
  • Dergi Adı: Human heredity
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, International Bibliography of Social Sciences, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.21-33
  • Anahtar Kelimeler: CHEK2 gene, Early-onset breast cancer, c.1103A > G, Variant of uncertain significance, GENETIC VARIANT, RISK, CLASSIFICATION, 1100DELC, ALLELE, WOMEN
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Introduction: The CHEK2 gene is known to be an important signal transducer involved in DNA repair, apoptosis, or cell cycle arrest in response to DNA damage. The mutations in this gene have been associated with a wide range of cancers, both sporadic and hereditary. Germline CHEK2 mutations are linked to an increased risk of breast cancer. Therefore, the aim of this study was to identify the prevalence of CHEK2 variants in BRCA1/2- and PALB2-negative early-onset patients with breast cancer and/or ovarian cancer in a Turkish population for the first time. Methods: The study included 95 patients with BRCA1/2- and PALB2-negative early-onset breast cancer and/or ovarian cancer and also 60 unaffected women. All the intron/exon boundaries and coding exons of CHEK2 were subjected to mutational analysis by heteroduplex analysis and DNA sequencing. Results: A total of 16 CHEK2 variants were found in breast cancer patients within the Turkish population. CHEK2 c.1100delC mutation most frequently studied in the CHEK2 gene was not detected in our study. The prevalence of variants of uncertain significance in CHEK2 was found to be 7.3% (n = 7) in BRCA1/2 and PALB2 mutation-negative Turkish patients with early-onset breast and/or ovarian cancer. Conclusion: The present study may shed light on alternative variations that could be significant for understanding the prevalence and clinical suitability of the CHEK2 gene.